Despite high expectations for the commonly used diabetes drug metformin to improve risk factors for heart disease in people without diabetes, few beneficial effects have been found in a randomised trial of patients with established cardiovascular disease, published in The Lancet Diabetes & Endocrinology.
A new way of using blood pressure-lowering medications could prevent more than a fourth of heart attacks and strokes - up to 180,000 a year - while using less medication overall, according to new research from the University of Michigan Health System and the VA Ann Arbor Healthcare System.
Loyola University Medical Center is the only Chicago hospital participating in a landmark clinical trial of an artificial aortic heart valve that does not require open heart surgery.
Therox has released results from its multicentre Investigational Device Exemption (IDE) pilot study of its next-generation system for supersaturated oxygen (SSO2) therapy. The results, which were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium (27 October–1 November, San Francisco, USA), had a 9.6% median infarct size measured at 30 days.
The OPEN II study and data from a series from the Amsterdam Medical Center, which were both presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference last week (27 October–1 November, San Francisco, USA), show that the Self-Apposing stent (Stentys) can be successfully used outside of its current indication of acute myocardial infarction.
Biotronik has announced that it has received the CE mark for its PK Papyrus covered coronary stent for the management of acute coronary artery perforation. According to a company press release, the PK Papyrus provides 58% greater flexibility and a 24% reduced crossing profile than Abbott Vascular’s Jostent Graftmaster.
Biosensors has announced that it has launched a larger version of its Axxess bifurcation drug-eluting stent. The new 4.0x9mm size received the CE mark in September and has been specifically designed for the safe and effective treatment of bifurcation lesions involving large main branch vessels and wide bifurcation angulation. The stent was launched at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium (27 October–1 November, San Francisco, USA).
Biosensors International has announced four- year results from the BioFreedom First in Man study (FIM), which demonstrated similar clinical outcomes between BioFreedomTM, a polymer-free drug-coated stent (DCS), and Boston Scientific s TaxusTM LibertéTM drug-eluting stent (DES), with no evidence of definite and/or probable stent thrombosis. Results were presented by Dr. Ricardo Costa, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, sponsored by the Cardiovascular Research Foundation.
According to a new study, aspirating blood clots does not significantly reduce microvascular obstruction or reduce the risk of death in patients with non-ST-elevation myocardial infarction (NSTEMI), when compared to standard percutaneous coronary intervention (PCI) without thrombectomy.
A clinical trial shows that rapidly cooling patients who have suffered ST-elevation myocardial infarction (STEMI, the most serious form of a heart attack) prior to restoring blood flow is safe and feasible. The findings of the CHILL-MI trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world s premier educational meeting specializing in interventional cardiovascular medicine.
In a clinical trial, a second-generation transcatheter aortic valve demonstrated low rates of complications that are sometimes seen in transcatheter aortic valve replacement (TAVR), including challenges with positioning, post-procedure paravalvular aortic regurgitation, vascular complications, and stroke.
Results of the DUTCH PEERS (TWENTE II) clinical trial demonstrate comparable safety and efficacy of two third-generation permanent polymer-based drug-eluting stents with low rates of adverse clinical events and establish the non-inferiority of the newest zotarolimus-eluting stent. The findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world s premier educational meeting specializing in interventional cardiovascular medicine.
A new study demonstrates that some patients may not need to receive prolonged anti-clotting therapy after drug-eluting stent (DES) implantation with the Endeavor zotarolimus-eluting stent, and that shortening the duration could reduce bleeding risks and treatment costs. The OPTIMIZE clinical trial findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world s premier educational meeting specializing in interventional cardiovascular medicine.
The first clinical trial in the United States to study the use of drug coated balloons (DCB) for femoropopliteal artery disease found the procedure is promising for safety and efficacy at six months. Six month data of the LEVANT 2 trial was presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world s premier educational meeting specializing in interventional cardiovascular medicine.
In the first head-to-head randomised controlled trial of third generation durable-polymer drug-eluting stents for the treatment of coronary artery disease in an all-comers patient population, the Resolute Integrity drug-eluting stent (Medtronic) and the Promus Element drug-eluting stent (Boston Scientific) performed similarly on all measures except longitudinal strength, which favoured the Resolute device.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos